Truvitech’s proprietary technology deploys machine learning and information theory in order to identify candidate drug targets. Having knowledge of one or more effective targets is critical for developing efficacious drugs, and is also valuable for designing synergistic drug combinations. 

In addition to identifying drug targets, the algorithm can also identify biological components whose engagement must be avoided to maximize therapeutic efficacy (anti-targets). Together, these features provide an unprecedented advantage for drug discovery programs.